How to Follow, Manage and Treat Cardiac Dysfunction in Patients With Her2+ Breast Cancer

Anne Blaes; Charlotte Manisty; Ana Barac

doi:10.1016/j.jaccao.2020.08.010

How to Follow, Manage and Treat Cardiac Dysfunction in Patients With Her2+ Breast Cancer

Anne Blaes, Charlotte Manisty, Ana Barac

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Review article › peer-review

Original language	English (US)
Pages (from-to)	661-665
Number of pages	5
Journal	JACC: CardioOncology
Volume	2
Issue number	4
DOIs	https://doi.org/10.1016/j.jaccao.2020.08.010
State	Published - Nov 2020

Keywords

breast cancer
cardiotoxicity
heart failure
HER2 targeted therapy
LV dysfunction
trastuzumab

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access

10.1016/j.jaccao.2020.08.010

Cite this

@article{5c4f54dc8f444091a978d776c256e5e1,

title = "How to Follow, Manage and Treat Cardiac Dysfunction in Patients With Her2+ Breast Cancer",

keywords = "breast cancer, cardiotoxicity, heart failure, HER2 targeted therapy, LV dysfunction, trastuzumab",

author = "Anne Blaes and Charlotte Manisty and Ana Barac",

year = "2020",

month = nov,

doi = "10.1016/j.jaccao.2020.08.010",

language = "English (US)",

volume = "2",

pages = "661--665",

journal = "JACC: CardioOncology",

issn = "2666-0873",

number = "4",

}

TY - JOUR

T1 - How to Follow, Manage and Treat Cardiac Dysfunction in Patients With Her2+ Breast Cancer

AU - Blaes, Anne

AU - Manisty, Charlotte

AU - Barac, Ana

PY - 2020/11

Y1 - 2020/11

KW - breast cancer

KW - cardiotoxicity

KW - heart failure

KW - HER2 targeted therapy

KW - LV dysfunction

KW - trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=85096323943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096323943&partnerID=8YFLogxK

U2 - 10.1016/j.jaccao.2020.08.010

DO - 10.1016/j.jaccao.2020.08.010

M3 - Review article

AN - SCOPUS:85096323943

VL - 2

SP - 661

EP - 665

JO - JACC: CardioOncology

JF - JACC: CardioOncology

SN - 2666-0873

IS - 4

ER -